Department of Obstetrics and Gynecology, People's Hospital, Peking University, Beijing 100044, China.
Chin Med J (Engl). 2020 Oct 5;133(19):2346-2352. doi: 10.1097/CM9.0000000000001063.
A clinically reliable non-invasive test for endometriosis is expected to reduce the diagnostic delay. Although varieties of biomarkers have been investigated for decades, and cancer antigen-125, cancer antigen-199, interleukin-6, and urocortin were the most studied ones among hundreds of biomarkers, no clinically reliable biomarkers have been confirmed so far. Some emerging technologies including "omics" technologies, molecular imaging techniques, and microRNAs are promising in solving these challenges, but their utility to detect endometriosis has yet to be verified. New combinations of researched indicators or other non-invasive methods and further exploration of the emerging technologies may be new targets and future research hotspots for non-invasive diagnosis of endometriosis. In conclusion, researches of biomarkers for the detection of endometriosis are still ongoing and may benefit from novel molecular biology, bioinformatics methods and a combination of more diverse monitoring methods. Though it will be a daunting task, the identification of a specific set of diagnostic biomarkers will undoubtedly improve the status of endometriosis.
人们期待一种临床可靠的非侵入性子宫内膜异位症检测方法，以减少诊断延误。尽管几十年来已经研究了多种生物标志物，数百种生物标志物中研究最多的是癌抗原 125、癌抗原 199、白细胞介素 6 和尿皮质素，但到目前为止还没有得到临床证实的可靠生物标志物。一些新兴技术，包括“组学”技术、分子成像技术和 microRNAs，在解决这些挑战方面很有前景，但它们用于检测子宫内膜异位症的效用仍有待验证。研究指标的新组合或其他非侵入性方法以及新兴技术的进一步探索可能是子宫内膜异位症非侵入性诊断的新目标和未来研究热点。总之，用于检测子宫内膜异位症的生物标志物的研究仍在进行中，可能受益于新的分子生物学、生物信息学方法以及更多样化监测方法的结合。虽然这将是一项艰巨的任务，但确定一组特定的诊断生物标志物无疑将改善子宫内膜异位症的状况。
